Atlas - A Handheld High Resolution Wide-field Retinal Imager

Atlas - 手持式高分辨率宽视场视网膜成像仪

• 批准号: 8524541
• 负责人: Paul Andrew Yates
• 金额: $ 22.5万
• 依托单位: RETIVUE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2015-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8524541
• 关键词: Adult; Affect; Anatomy; Area; Atlases; Birth Weight; Blindness; Caliber; Child; Childhood; Clinical; Contact Lenses; Custom; Detection; Developed Countries; Developing Countries; Devices; Diagnosis; Diagnostic; Diagnostic Equipment; Dimensions; Direct Costs; Disease; Early treatment; Economics; Engineering; Ensure; Eye; Eye diseases; Facilities and Administrative Costs; Future; Gestational Age; Glass; Hand; Hand functions; Hospitals; Human; Image; Imagery; Imaging technology; Impairment; Infant; Lasers; Light; Lighting; Marketing; Measures; Medical; Methods; Metric; Modeling; Neonatal; Neonatal Intensive Care Units; Nurses; Ocular orbit; Ophthalmologist; Optics; Pathology; Patients; Peripheral; Persons; Phase; Photography; Positioning Attribute; Premature Infant; Resolution; Retina; Retinal; Retinal Diseases; Retinopathy of Prematurity; Risk; Solutions; Source; Specialist; Sterility; Sterilization; Structure; Surface; System; Technology; Telemedicine; Time; Touch sensation; Traction; Training; Universities; Very Low Birth Weight Infant; Virginia; Vision; Visual impairment; Weight; Wireless Technology; Work; World Health Organization; base; blind; cost; cost effective; design; digital; face bone structure; improved; innovation; lens; meetings; millimeter; novel; optical imaging; portability; prevent; programs; prototype; public health relevance; research clinical testing; screening; seal; sensor; standard of care; success; tertiary care

7. Project Summary Retinopathy of prematurity (ROP) is a treatable eye disease which affects the vision of neonatal infants with a birth weight of <1500g or gestational age of <30 weeks. There are 28,000 infants born each year in the US at risk for developing ROP. However, even with advanced treatments available 400 to 600 of these infants be- come blind each year. Globally, there are more than 50,000 documented cases of preventable childhood blindness due to ROP. The World Health Organizataion has thus declared ROP a leading cause of vision im- pairment in children. These high numbers can be primarily attributed to inadequate screening of these infants due in part to the low numbers of pediatric-trained ophthalmologists and ROP diagnostic equipment in neonatal intensive care units (NICUs). Recent studies suggest that tele-screening with wide-angle retinal photography in combination with early treatment practices may be an economically feasible, cost-saving measure for im- proving the current standard of care for ROP, preventing many cases of needless blindness. In this application, RetiVue LLC proposes to develop the Atlas, a low cost (<$5,000 market cost), high resolu- tion, hand-held device capable of wide-field imaging of the retina for easily diagnosing and screening for ROP. Our unique design approach leverages novel retinal imaging technology developed at the University of Virginia that enables an extremely low cost device capable of capturing a 120¿ retinal field which may find use in tele- retinal ROP screening programs. Using this technology, we will first engineer a wide-angle objective lens module capable of providing a continuously illuminated 120¿ view of the infant retina. This lens module will be designed such that the contacting surface will be physically compatible with the unique anatomical structure of the infant eye and surrounding facial bone structure. An alpha-prototype will then be constructed which inte- grates the objective lens module with a common consumer digital camera with customized firmware for image capture. The Atlas prototype will emphasize a lightweight (<1.25lbs) design with a compact, hand-held form factor. Work completed during this Phase I application in addition to subsequent clinical testing will lay the technical foundation onto which the world's first simple-to-manufacture, affordable, highly portable, and easy-to-use ROP screening device can be commercialized. We hope that this highly disruptive device can help overcome the primary economic and technological access barriers to establishing successful ROP tele-screening pro- grams within NICUs in developed and developing countries alike.

七、项目概要 早产儿视网膜病变 (ROP) 是一种可治疗的眼部疾病，会影响新生儿的视力。 出生体重<1500克或胎龄<30周。美国每年有 28,000 名婴儿出生 发生 ROP 的风险。然而，即使采用先进的治疗方法，仍有 400 至 600 名婴儿仍处于死亡状态。 每年都会失明。在全球范围内，有超过 50,000 起可预防的童年案例记录在案 ROP 导致失明。世界卫生组织因此宣布 ROP 是导致视力下降的主要原因。 儿童配对。这些高数字主要归因于对这些婴儿的筛查不充分 部分原因是受过儿科培训的眼科医生和新生儿 ROP 诊断设备的数量较少 重症监护病房 (NICU)。最近的研究表明，使用广角视网膜摄影进行远程放映 结合早期治疗实践可能是经济上可行的、节省成本的措施 证明了当前 ROP 的护理标准，防止了许多不必要的失明病例。 在此应用中，RetiVue LLC 提议开发 Atlas，这是一款低成本（<5,000 美元市场成本）、高分辨率的 化，手持式设备，能够对视网膜进行宽视野成像，以便轻松诊断和筛查 ROP。 我们独特的设计方法利用了弗吉尼亚大学开发的新颖的视网膜成像技术 这使得一种成本极低的设备能够捕获 120° 的视网膜视野，这可能会在远距离拍摄中使用。 视网膜 ROP 筛查计划。利用这项技术，我们将首先设计一个广角物镜 模块能够提供婴儿视网膜的连续照明 120° 视图。该镜头模块将 设计使得接触表面与独特的解剖结构物理兼容 婴儿的眼睛和周围的面部骨骼结构。然后将构建一个 alpha 原型，其中包含 使用具有定制图像固件的普通消费级数码相机来光栅物镜模块 捕获。 Atlas原型将强调轻量级（<1.25磅）设计以及紧凑的手持式形式 因素。 除了随后的临床测试之外，在第一阶段申请期间完成的工作将为技术奠定基础 世界上第一个制造简单、价格实惠、高度便携且易于使用的产品奠定了基础 ROP筛选装置可商品化。我们希望这种极具颠覆性的设备能够帮助克服 建立成功的 ROP 电视放映项目的主要经济和技术准入障碍 发达国家和发展中国家新生儿重症监护病房 (NICU) 内的克数均相同。